Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Announces Approval for Isoproterenol Hydrochloride Injection, USP
RANCHO CUCAMONGA, Calif. , June 19, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“ANDA”) for Isoproterenol Hydrochloride Injection, USP 0.2mg/mL,
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference 2018
RANCHO CUCAMONGA, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters , CFO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 5, 2018 at 3:00 p.m. Eastern Time in New York, NY .
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Semi-Purified Heparin at Amphastar Nanjing Pharmaceuticals
RANCHO CUCAMONGA, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) supplement for the manufacture of semi-purified heparin
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection
RANCHO CUCAMONGA, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Calcium Chloride injection 10% in the 10 mL Luer-Jet
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
RANCHO CUCAMONGA, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
Reports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018 RANCHO CUCAMONGA, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2018 .
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018
RANCHO CUCAMONGA, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018 , after the market closes on Wednesday, May 9, 2018 , and will hold a conference call to
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference
RANCHO CUCAMONGA, Calif. , March 26, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters , CFO will be presenting at the Needham‘s 17 th Annual Healthcare Conference on Wednesday, March 28, 2018 at 9:30 a.m. Eastern Time in New York, NY .
View HTML
Toggle Summary Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
RANCHO CUCAMONGA, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on March 20, 2018 , the United States Court for the District of Massachusetts (the “District Court”) entered final judgment in favor of Amphastar in a lawsuit brought by
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017
Reports Net Revenues of $60.4 Million for the Three Months Ended December 31, 2017 RANCHO CUCAMONGA, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months and fiscal year ended December
View HTML

 

Copyright ©2018 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States